PATENT CLAIM ANALYSIS

Application Number: 16010755
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["548", "245000"]

Abstract:
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Claim (Index 18):
The compound according to  claim 17 , wherein:\n R A  is \u2014CO 2 H; L 1  is in the ring R H  is \u2014F;\n in the ring \n A 1  is C and R H  is \u2014H;\n Ring A has the structure of \n R C  is \u2014F; R F  is \u2014H; R G  is \u2014CH 3 ; and in the CY ring R H  is \u2014Cl.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.61224
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16000283', '14776954', '13388502', '13133636', '14755383']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7887348034843618
- 35 USC 102 Novelty (BERT): 0.5582415492826862
- Combined Prediction Score: 0.7656854780641943
- Mean Citation Score: 381.080306
- Max Citation Score: 479.01657
- Similarity Product: 312.84235935501687

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test